Efficacy of Simultaneous Infusion of Tirofiban with Intravenous Thrombolysis in Patients with Acute Anterior Choroidal or Paramedian Pontine Infarction
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background and Purpose
Intravenous thrombolysis combined with tirofiban (IVT+T) has been reported to be more effective than IVT alone (IVTa) in preventing early neurological deterioration (END) and improving 3-month functional outcomes in patients with ischemic stroke. This study aimed to assess the radiological efficacy and safety of simultaneous (or within 60 minutes) IVT+T versus IVTa specifically in patients with anterior choroidal infarction (ACI) or paramedian pontine infarction (PPI), two subtypes with a high risk of END.
Methods
We conducted a single-center, retrospective study including consecutive patients aged ≥18 years treated during two distinct periods: one with standard IVT alone and one with IVT+T. The primary endpoint was ≥20% reduction in lesion volume on 24-hour diffusion-weighted imaging (DWI). Secondary endpoints included early clinical improvement at 24 hours and 7 days (or discharge), functional independence (modified Rankin Scale (mRS) scores ≤2 and ≤1) at 3 months, and END. Safety outcomes included symptomatic intracranial hemorrhage (sICH) and major systemic bleeding (MSB). A subgroup analysis compared clinical outcomes in patients with reversion versus patients with no reversion.
Results
A total of 58 patients were analyzed (30 IVT+T; 28 IVTa). Lesion reversal ≥20% was more frequently observed in the IVT+T group (adjusted odds ratio, 8.58; 95% CI, 2.09–35.28; p=0.001). No significant differences were found between groups for END or 3-month functional outcomes (mRS ≤2 or ≤1). One non-fatal MSB occurred in the IVTa group. No cases of sICH were observed in either group. Reversion overall was significantly associated with better early and late outcomes, and with IVT+T treatment.
Conclusions
This study suggests that IVT+T improves radiological outcomes and may be a promising therapeutic option in patients with ACI/PPI, without increasing the risk of bleeding compared to IVTa.
Clinical Trial Registration
This study is registered with ClinicalTrials.gov , URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05733507 .
